-+ 0.00%
-+ 0.00%
-+ 0.00%

Caribou Biosciences Q3 net loss narrows to $26.61 million; Q3 revenue falls 27% to $1.61 million

PUBT·11/05/2026 21:44:16
Listen to the news
Caribou Biosciences Q3 net loss narrows to $26.61 million; Q3 revenue falls 27% to $1.61 million
  • Caribou Biosciences’ third-quarter 2026 GAAP net loss narrowed year over year to $26.61 million.
  • Revenue fell 27% to $1.61 million, while total operating expenses declined 7% to $29.25 million year over year.
  • Cash, cash equivalents, and marketable securities dropped 34% to $94.8 million at September 30, 2026, from December 31, 2025.
  • An October 6 restructuring announcement outlined plans to discontinue vispa-cel and CB-011 development while exploring strategic alternatives, including dissolution and liquidation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051605PRIMZONEFULLFEED9870803) on November 05, 2026, and is solely responsible for the information contained therein.